Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting beneficial ownership of 9,108,019 shares of Ionis Pharmaceuticals common stock, representing 5.6% of the outstanding class as of the event date.
The firm reports sole voting power over 9,083,319 shares and sole dispositive power over 9,108,019 shares, with no shared voting or dispositive authority. It certifies the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Ionis Pharmaceuticals, and includes a legal disclaimer that it is not admitting beneficial ownership.
Ionis Pharmaceuticals executive files corrective Form 4/A. EVP and Chief Scientific Officer C. Frank Bennett reports that an earlier filing on February 4, 2026 mistakenly showed a sale of 20,000 common shares and the exercise of 65,089 stock options. These transactions were executed in error and fully reversed on February 12, 2026.
Following the reversal, Bennett is shown as directly beneficially owning 100,293 shares of Ionis Pharmaceuticals common stock as of February 12, 2026. The current filing uses a corrective "J" transaction code with zero shares at a price of $0.0 to document the adjustment.
Ionis Pharmaceuticals EVP Research Eric Swayze reported preset stock sales. On February 13, 2026, he executed two open-market sales of Ionis common stock under a Rule 10b5-1 trading plan adopted on August 14, 2024.
The transactions totaled 9,435 shares at $81.5592 and 6,207 shares at $82.0691 weighted-average prices. After these sales, Swayze held 32,105 shares directly and 318 shares indirectly through his son.
Ionis Pharmaceuticals director B. Lynne Parshall reported an open-market sale of common stock. On February 11, 2026, Parshall sold 5,000 shares of Ionis common stock at a weighted average price of $82.7177 per share under a pre-established Rule 10b5-1 trading plan adopted on May 6, 2025. After this transaction, Parshall directly beneficially owns 56,344 shares of Ionis common stock.
Ionis Pharmaceuticals shareholder Eric Swayze has filed a notice of proposed sale of 15,642 shares of common stock under Rule 144. The shares, to be sold through Stifel Nicolaus & Company Inc. on Nasdaq around 02/13/2026, have an aggregate market value of $1,277,169.00. The filing notes that 161,974,393 shares of Ionis common stock were outstanding. These 15,642 shares were acquired on 01/15/2026 as restricted stock units granted by the issuer as equity compensation. Over the prior three months, Swayze sold additional Ionis common stock in three transactions totaling 39,526 shares for gross proceeds of $3,122, - combining reported amounts of $1,853,577.00, $753,501.00, and $512,906.00.
Ionis Pharmaceuticals (symbol IONS) has an insider planning to sell 10,000 shares of common stock through broker Stifel Nicolaus & Company on or around February 11, 2026 on the Nasdaq market. The filing lists an aggregate market value of $827,400 for these planned sales.
The securities relate to common stock originally acquired on January 15, 2017 as restricted stock units granted by the issuer as equity compensation. The notice also states that the person signing does not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
Ionis Pharmaceuticals Inc. Chief Executive Officer and director Brett P. Monia reported selling 29,430 shares of common stock on February 6, 2026 at a weighted average price of $85.7907 per share. The sale was carried out under a pre-established Rule 10b5-1 trading plan adopted on August 13, 2024. Following this transaction, Monia beneficially owned 254,497 shares of Ionis common stock in direct form.
IONS filer Brett Monia submitted a Rule 144 notice for the proposed sale of 290,203 shares of common stock through Stifel Nicolaus & Company Inc. on or about 02/06/2026 on Nasdaq, with an aggregate market value of 24826867.00.
The shares to be sold were acquired on 01/15/2026 as restricted stock units from the issuer as equity compensation. The notice states that 161,974,393 shares of this class were outstanding. During the prior three months, Monia sold 44,034 and 62,970 shares of common stock for gross proceeds of 3357167.00 and 5223749.00, respectively.
Ionis Pharmaceuticals executive C. Frank Bennett reported option exercises and stock sales. As EVP and Chief Scientific Officer, he exercised non-qualified stock options for 48,626 shares at $60.89 and 16,463 shares at $32.6, then converted them into common stock.
On the same date, he sold 20,000 shares at a weighted-average price of $82.599 and sold 48,626 and 16,463 shares at a weighted-average price of $83.0284, in multiple trades within disclosed price ranges. After these transactions, he directly owned 80,293 common shares and 2,406 option shares.
Ionis Pharmaceuticals executive Eric Swayze reported equity transactions in company stock. On January 29, 2026, he acquired 11,991 shares of common stock at $0.0 per share from the vesting of performance-based restricted stock units, after the Compensation Committee certified achievement of the relative total shareholder return goal at 167.27% of target shares.
On January 30, 2026, he sold 6,179 shares of Ionis common stock at a weighted average price of $82.9335 per share, in multiple transactions within a narrow price range. Following these transactions, he directly beneficially owned 47,747 shares, and an additional 318 shares were held indirectly by his son.